Gilead Sciences Surges to 107th in Trading Volume with $864 Million Turnover

On May 27, 2025, Gilead Sciences (GILD) experienced a significant surge in trading volume, with a total turnover of $864 million, marking a 33.77% increase from the previous day. This substantial rise in trading activity positioned Gilead as the 107th most actively traded stock for the day. The company's stock price also saw a notable increase, rising by 1.60% over the past two days, with a cumulative gain of 2.20%.

Gilead Sciences recently announced positive data from the phase III ASCENT-03 trial for its drug Trodelvy. The trial demonstrated a significant improvement in progression-free survival (PFS) for patients with first-line metastatic triple-negative breast cancer (TNBC). This outcome reinforces Trodelvy's potential as a backbone therapy for this patient population. The study's results showed highly statistically significant and clinically meaningful improvements, meeting its primary endpoint and highlighting the drug's efficacy in extending PFS.

This positive data from the ASCENT-03 trial is expected to bolster investor confidence in Gilead's oncology portfolio, particularly in the treatment of metastatic TNBC. The successful outcomes from this trial could pave the way for further regulatory approvals and expanded use of Trodelvy, potentially driving future revenue growth for the company. Investors are likely to view these developments favorably, as they indicate Gilead's continued innovation and leadership in the biopharmaceutical sector.